KEVEYIS (dichlorphenamide)
Keveyis is an oral medication used for patients living with primary hyperkalemic or hypokalemic periodic paralysis. It also helps those with related variants of these conditions. This drug is prescribed to help manage these specific forms of periodic paralysis.
How KEVEYIS Works
Keveyis works by inhibiting carbonic anhydrase. While it belongs to this specific class of inhibitors, the exact process by which it produces its therapeutic effects in patients with primary periodic paralysis remains unknown.
Details
- Status
- Prescription
- First Approved
- 1958-07-22
- Routes
- ORAL
- Dosage Forms
- TABLET
KEVEYIS Approval History
What KEVEYIS Treats
2 indicationsKEVEYIS is approved for 2 conditions since its original approval in 1958. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hyperkalemic Periodic Paralysis
- Hypokalemic Periodic Paralysis
KEVEYIS Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to KEVEYIS
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KEVEYIS FDA Label Details
Indications & Usage
FDA Label (PDF)KEVEYIS is indicated for the treatment of Hyperkalemic Periodic Paralysis; Hypokalemic Periodic Paralysis.
Track KEVEYIS with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.